Larimar Therapeutics, Inc.
- Open
- 3.05
- Day high
- 3.25
- Day low
- 3.00
- Prev close
- 3.05
- Volume
- 1.2M
- Mkt cap
- $324M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.0
- P/S
- —
- Yield
- —
- Per share
- —
Larimar Therapeutics, Inc. (LRMR) is a Healthcare company listed on NASDAQ. The stock is up 21% over the past year.
Larimar Therapeutics, Inc. (LRMR) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
LRMR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.53 | $-0.31 | +41.5% | — | — |
| Mar 19, 2026 | $-0.44 | $-0.73 | -65.9% | — | — |
| Nov 5, 2025 | $-0.39 | $-0.61 | -56.4% | — | — |
| Aug 14, 2025 | $-0.47 | $-0.41 | +12.8% | — | — |
| Apr 30, 2025 | $-0.42 | $-0.46 | -9.5% | — | — |
| Mar 24, 2025 | $-0.29 | $-0.45 | -55.2% | $241000 | — |
| Oct 30, 2024 | $-0.37 | $-0.24 | +35.1% | — | — |
| May 9, 2024 | $-0.24 | $-0.27 | -12.5% | — | — |
| Mar 14, 2024 | $-0.25 | $-0.30 | -20.0% | — | — |
| Nov 14, 2023 | $-0.23 | $-0.21 | +8.7% | — | — |
| Aug 10, 2023 | $-0.21 | $-0.19 | +9.5% | — | — |
| May 15, 2023 | $-0.25 | $-0.15 | +40.0% | — | — |
LRMR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 20, 2026 | SHERMAN JEFFREY Wdirector | Grant | 55,150 | $3.33 |
| May 20, 2026 | Truitt Josephdirector | Grant | 55,150 | $3.33 |
| May 20, 2026 | LEFF JONATHAN Sdirector | Grant | 55,150 | $3.33 |
| May 20, 2026 | THOMAS FRANK Edirector | Grant | 55,150 | $3.33 |
| May 20, 2026 | Hamilton Thomas Edwarddirector | Grant | 55,150 | $3.33 |
| May 20, 2026 | Flynn James Edirector, 10 percent owner, other: * Director by Deputization | Grant | 55,150 | $3.33 |
| Mar 2, 2026 | Flynn James Edirector, 10 percent owner, other: * Director by Deputization | Buy | 1,084,012 | $5.00 |
| Mar 2, 2026 | SHERMAN JEFFREY Wdirector | Buy | 5,000 | $5.00 |
| Mar 2, 2026 | THOMAS FRANK Edirector | Buy | 5,000 | $5.00 |
| Mar 2, 2026 | Hamilton Thomas Edwarddirector | Buy | 100,000 | $5.00 |
| Mar 2, 2026 | Flynn James Edirector, 10 percent owner, other: * Director by Deputization | Buy | 1,084,010 | $5.00 |
| Mar 2, 2026 | Flynn James Edirector, 10 percent owner, other: * Director by Deputization | Buy | 2,000,000 | $5.00 |
| Mar 2, 2026 | Flynn James Edirector, 10 percent owner, other: * Director by Deputization | Buy | 831,978 | $5.00 |
| Jan 27, 2026 | BEN-MAIMON CAROLEdirector, officer: President and CEO | Grant | 100,100 | — |
| Jan 27, 2026 | Shankar Gopiofficer: Chief Development Officer | Grant | 153,822 | $3.60 |
Source: LRMR SEC Form 4 filings, latest May 20, 2026. For informational purposes only — not investment advice.
See the full LRMR insider & 13F page →Larimar Therapeutics, Inc. company profile
Overview
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company founded in 2014 and based in Bala Cynwyd, Pennsylvania. The company specializes in developing innovative treatments for rare diseases using its proprietary cell penetrating peptide technology platform. Since going public in 2014, Larimar has focused its efforts on advancing novel therapeutic approaches for conditions that currently have limited or no treatment options, with its lead program targeting Friedreich's ataxia, a devastating genetic disorder.
Business
Larimar Therapeutics operates in the biotechnology sector, specifically focusing on rare disease drug development. The company's core expertise lies in its proprietary cell penetrating peptide (CPP) technology platform, which represents an innovative approach to drug delivery that can potentially overcome barriers that prevent traditional medications from reaching their intended targets within cells. Cell penetrating peptides are short sequences of amino acids that have the unique ability to cross cell membranes and deliver therapeutic cargo directly into cells. This technology is particularly valuable because many diseases are caused by problems within cells that are difficult to reach with conventional drugs. Traditional medications often struggle to penetrate cell membranes effectively, limiting their therapeutic potential. The company's lead product candidate is CTI-1601, which is currently in Phase 1 clinical trials for the treatment of Friedreich's ataxia. Friedreich's ataxia is a rare, progressive, and ultimately fatal genetic disease that affects the nervous system and causes movement problems. The condition is caused by mutations in the FXN gene, which leads to reduced production of a protein called frataxin. Without adequate frataxin, cells cannot properly produce energy, leading to progressive damage to the nervous system, heart, and other organs. Patients typically experience loss of coordination, muscle weakness, and speech problems, with symptoms usually appearing in childhood or adolescence. Currently, Larimar appears to be a single-program company with CTI-1601 representing essentially 100% of its development focus and potential future revenue opportunity.
Revenue model
As a clinical-stage biotechnology company, Larimar Therapeutics does not currently generate meaningful revenue from product sales. The company's business model is built around developing its drug candidates through clinical trials with the ultimate goal of obtaining regulatory approval and either commercializing the products directly or licensing them to larger pharmaceutical companies. The company's revenue potential depends entirely on the successful development and eventual commercialization of CTI-1601. If approved, the drug could generate revenue through direct sales to patients, hospitals, and healthcare systems. Given that Friedreich's ataxia is a rare disease affecting approximately 1 in 50,000 people, the addressable market is relatively small but could command premium pricing due to the lack of alternative treatments. Several factors could significantly impact Larimar's financial prospects and margins. Positive clinical trial results would dramatically increase the company's value and potential revenue, while negative results could effectively eliminate its primary value proposition. Regulatory approval timelines directly affect when the company might begin generating revenue, with delays extending the cash burn period. Competition from other rare disease treatments or alternative approaches to treating Friedreich's ataxia could reduce market share and pricing power. Additionally, manufacturing and scaling costs for the cell penetrating peptide technology could impact gross margins, while reimbursement policies from insurance companies and government healthcare systems will determine the accessible market size and pricing levels. The company's current financial model involves raising capital through equity offerings and potentially partnerships to fund research and development activities until a product reaches market or can be licensed to a partner.
Competitive moat
Larimar Therapeutics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages or moats. The company's primary potential moat lies in its proprietary cell penetrating peptide technology platform, which could provide some differentiation if proven effective. However, this technology advantage is relatively narrow and unproven at scale. The company does benefit from being one of the few organizations specifically targeting Friedreich's ataxia with an advanced clinical program, providing some first-mover advantage in this rare disease space. The regulatory pathway for rare diseases can also create temporary competitive protection through orphan drug designations, which provide market exclusivity periods and development incentives. However, Larimar's moat is quite weak overall. The biotechnology sector is characterized by rapid innovation, and larger pharmaceutical companies with significantly greater resources could potentially develop competing approaches or acquire smaller competitors. The company's single-program focus creates concentration risk, as failure of CTI-1601 would essentially eliminate its competitive position. Additionally, academic institutions and other biotech companies are actively researching alternative treatments for Friedreich's ataxia and other rare diseases, potentially developing superior approaches. The cell penetrating peptide technology, while innovative, is not uniquely held by Larimar, and other companies are exploring similar delivery mechanisms. Without a diversified pipeline or substantial intellectual property portfolio, the company remains vulnerable to competitive threats and technological disruption. The moat is primarily dependent on execution risk and timing rather than fundamental competitive advantages.
Risks & safety
Larimar Therapeutics presents significant financial risks typical of clinical-stage biotechnology companies, with limited margin of safety for investors. • Cash position and burn rate: The company had $21.1 million in cash as of Q1 2025, down from $33.2 million in Q4 2024. With quarterly cash burn of approximately $26-27 million based on recent operating cash flows, the company has less than one quarter of runway remaining at current spending levels. • Debt and solvency: Minimal debt with debt-to-equity ratio of only 0.034, indicating low leverage risk. However, the rapid cash burn creates immediate solvency concerns requiring additional financing. • Valuation metrics: Trading at 0.95x book value and negative earnings multiples due to losses. Current ratio of 7.5x indicates strong short-term liquidity relative to current liabilities. • Other considerations: The company generated minimal revenue ($241K in Q4 2024), making it entirely dependent on clinical trial success and future financing. The stock price has declined significantly from over $8 in Q3 2024 to $2.65 currently, reflecting investor concerns about the cash runway and clinical progress.
Recent development
Based on the available financial data, Larimar Therapeutics has been primarily focused on advancing its lead program CTI-1601 through clinical development for Friedreich's ataxia. The company has maintained its single-program focus while managing the typical challenges of clinical-stage biotechnology development. The most significant recent development appears to be the progression of CTI-1601 into Phase 1 clinical trials, representing a critical milestone for the company. The financial statements show the company has been investing heavily in research and development activities, with consistent quarterly losses in the $15-30 million range reflecting active clinical trial operations and associated costs. The company's cash position has fluctuated significantly, suggesting it has likely completed equity financing rounds during this period to fund operations. The increase in total assets from approximately $95 million at the end of 2023 to over $200 million by mid-2024, followed by a decline to $170 million by Q1 2025, indicates substantial capital raising followed by operational spending. Without access to detailed earnings call transcripts, the specific strategic decisions and clinical milestones achieved during this period are not fully apparent from the financial data alone. However, the sustained high level of spending suggests active clinical trial activities and continued investment in the core CTI-1601 program.
LRMR company profile · for informational purposes only — not investment advice.
Track LRMR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free